GlassScriptPhysician profile
Mark J Nicaud
NPI 1598927667
$15,156.51
in general payments reported to CMS, 2019-2025
42 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,820 · 2020: $1,612 · 2021: $2,454 · 2022: $2,221 · 2023: $1,966 · 2024: $2,709 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,048.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,349.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,877.03 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,306.56 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $1,248.35 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $934.43 | 2019-2025 | |
| Celgene Corporation | $822.20 | 2021-2024 | Zeposia |
| Pfizer INC. | $675.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $441.72 | 2019-2024 | Dificid |
| Qol Medical, LLC | $367.39 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $334.48 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $322.52 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $319.14 | 2023-2025 | Omvoh |
| Boston Scientific Corporation | $248.21 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $238.93 | 2019-2025 | Ocaliva |
| Daiichi Sankyo INC. | $179.02 | 2019-2025 | Injectafer |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,648.97 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nicaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.